Bioequivalence of two rabeprazole formulations and pharmacokinetic variability by CYP2C19 genotype and sex in healthy Korean participants: A four‐period replicated crossover study
Clinical Pharmacology in Drug Development · 2026
DOI: 10.1002/cpdd.70099 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Nakyong Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Rabeprazole, Cytochrome P-450 CYP2C19, Drugs, Generic, Proton Pump Inhibitors. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Daewoong Bio Inc..
Abstract (Originalsprache)
Rabeprazole is a highly variable drug for which demonstration of bioequivalence is often challenging, and CYP2C19 genotype and sex have been suggested as potential contributors to pharmacokinetic variability. We evaluated the pharmacokinetics, bioequivalence (BE), and tolerability of a generic rabeprazole formulation compared with the reference product in healthy Korean participants using an open‐label, randomized, single‐dose, two‐sequence, four‐period replicated crossover design with a scaled average BE (SABE) approach. Exploratory subgroup analyses according to CYP2C19 genotype and sex were also performed. Fifty‐two participants received single 20 mg doses under fasting conditions, and 46 completed the trial. BE was evaluated using SABE and conventional average BE (ABE), with subgroup analyses by genotype and sex. Geometric mean ratios (GMRs) of the test to reference formulations were within the BE acceptance range under ABE and SABE approaches. The reference formulation showed high intra‐CV in maximum plasma concentration ( C max ; 67.9%), consistent with the classification of rabeprazole as a highly variable drug. These results demonstrated bioequivalence between the test and reference formulations under both conventional average bioequivalence and scaled bioequivalence approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
- Kidney Research Institute, Seoul National University Medical Research Center, Seoul, Republic of Korea.
- Department of Pharmacology, Kangwon National University School of Medicine, Chuncheon, Republic of Korea.
Förderung
- Daewoong Bio Inc.
Zitieren
APA
Lee, N., Cho, J. Y., & Kim, B. (2026). Bioequivalence of two rabeprazole formulations and pharmacokinetic variability by CYP2C19 genotype and sex in healthy Korean participants: A four‐period replicated crossover study. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70099
Vancouver
Lee N, Cho JY, Kim B. Bioequivalence of two rabeprazole formulations and pharmacokinetic variability by CYP2C19 genotype and sex in healthy Korean participants: A four‐period replicated crossover study. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70099
BibTeX
@article{Lee2026,
author = {Lee, Nakyong and Cho, Joo-Youn and Kim, Byungwook},
title = {Bioequivalence of two rabeprazole formulations and pharmacokinetic variability by CYP2C19 genotype and sex in healthy Korean participants: A four‐period replicated crossover study},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
doi = {10.1002/cpdd.70099}
}
EUVIMED